Page last updated: 2024-11-05

3-toluic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Toluic acid, also known as m-toluic acid, is a white crystalline solid with a melting point of 111-112 °C. It is an organic compound with the formula C8H8O2, consisting of a benzene ring substituted with a methyl group (CH3) at the 3-position and a carboxyl group (COOH). 3-Toluic acid is an important intermediate in the production of various pharmaceuticals, dyes, and polymers. It is also used as a flavoring agent and preservative in food. Synthesis of 3-toluic acid typically involves the oxidation of m-xylene, a petroleum-derived compound, using potassium permanganate or chromic acid. 3-Toluic acid has been studied extensively for its biological activity, including its potential as an anti-inflammatory agent and its role in plant growth regulation. Due to its aromatic structure and carboxyl group, 3-toluic acid can exhibit antimicrobial properties and has potential applications in the development of novel antimicrobial agents.'

3-toluic acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7418
CHEMBL ID67450
CHEBI ID10589
SCHEMBL ID14406
MeSH IDM0054278

Synonyms (77)

Synonym
CHEBI:10589 ,
beta-methylbenzoic acid
3-toluic acid
meta-toluic acid
3-methylbenzoic acid
m-methylbenzoic acid
nsc-2214
nsc2214
benzoic acid, 3-methyl-
NCIOPEN2_000993
brn 0970526
einecs 202-723-9
ai3-15626
nsc 2214
AB-131/40222909
benzoic acid,3-methyl
inchi=1/c8h8o2/c1-6-3-2-4-7(5-6)8(9)10/h2-5h,1h3,(h,9,10
NCGC00091271-01
C07211
m-toluylic acid
99-04-7
m-toluic acid ,
beta-bethylbenzoic acid
m-toluic acid, reagentplus(r), 99%
NCGC00091271-02
STK397307
CHEMBL67450 ,
3-methyl-benzoic acid
BMSE000553
T0291
AKOS000120442
NCGC00091271-03
dtxsid1021617 ,
tox21_302796
NCGC00256583-01
dtxcid401617
cas-99-04-7
NCGC00259140-01
tox21_201591
bdbm50405326
unii-1ua7k8eext
1ua7k8eext ,
FT-0629015
m-toluic acid [mi]
3-methylbenzic acid
m-methyl-benzoic acid
meta-methylbenzoic acid
SCHEMBL14406
W-100055
3-toluic acid, barium salt
3-toluic acid, cadmium salt
3-toluic acid, zinc salt
3-methylbenzoicacid
F2191-0114
mfcd00002523
m-toluic acid, vetec(tm) reagent grade, 98%
meta toluic acid
Z57913535
m-toluicacidforsynthesis
b-bethylbenzoic acid
3-methyl-benzoate
beta-methylbenzoate
meta-toluate
b-methylbenzoate
b-methylbenzoic acid
m-toluylate
b-bethylbenzoate
3-methylbenzoic acid(flakes or chunks or granular)
CS-0008583
AS-10810
Q1241221
EN300-18413
D70873
m-toluic-d7 acid
ovv ,
m-toluicacid
ow9 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methylbenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.18690.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency54.30970.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency54.30970.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency0.38100.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency10.14700.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency13.51860.013326.981070.7614AID1346978
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency56.23410.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.67210.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.10060.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency17.01890.001530.607315,848.9004AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency9.57040.005428.02631,258.9301AID1346982
caspase-3Homo sapiens (human)Potency13.51860.013326.981070.7614AID1346978
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.17420.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency39.63160.039147.5451146.8240AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.60390.000323.4451159.6830AID743065
Nuclear receptor ROR-gammaHomo sapiens (human)Potency2.98490.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1149945Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID226477Hammett constant was determined1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID28497log (1/C') was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1698309Dissociation constant, pKa of compound in water by Sirius T3 apparatus based potentiometric titration analysis2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Fragment based drug design and diversity-oriented synthesis of carboxylic acid isosteres.
AID29132pI50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28693Concentration of the drug in the liver of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID226478Hammett constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID1698308Distribution coefficient, logD of compound at pH 8 by Sirius T3 apparatus based potentiometric titration analysis2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Fragment based drug design and diversity-oriented synthesis of carboxylic acid isosteres.
AID1698307Distribution coefficient, logD of compound at pH 3 by Sirius T3 apparatus based potentiometric titration analysis2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Fragment based drug design and diversity-oriented synthesis of carboxylic acid isosteres.
AID28692Concentration of the drug in the kidney of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (39.58)18.7374
1990's14 (29.17)18.2507
2000's6 (12.50)29.6817
2010's7 (14.58)24.3611
2020's2 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.46 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index1.67 (0.95)

This Compound (27.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]